Clinical Trials Browser

Phase 2 × beta-Thalassemia × 90 days × Clear all

NCT05736419 2026-03-05

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase 2 Recruiting

Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia